Movement Alert｜BEONE MEDICINES Intraday Rise 3.94% in Regular Trading, Clinical Collaboration with Revolution Medicines on RAS Combination Therapies

Market Focus08-11

On August 11, BEONE MEDICINES rose 3.94% in regular trading, trading at 221.2 HKD/share, with turnover of HKD 157 million.

On the news front, BEONE MEDICINES announced a clinical collaboration agreement with Revolution Medicines to jointly evaluate combination therapy regimens pairing the company's clinical-stage oncology candidates with one or more of Revolution Medicines' four clinical-stage RAS(ON) inhibitors, targeting the historically \"undruggable\" RAS pathway in cancer treatment.

The collaboration follows a period of strong momentum for the company. BEONE MEDICINES reported Q2 global revenue of USD 1.705 billion, up 30% year-over-year, with GAAP net profit of USD 237 million, representing 151% growth. The company raised its full-year revenue guidance to RMB 449-462 billion. Multiple institutions including CLSA, CICC, Bank of America, and BOCOM International have recently upgraded target prices, with CLSA setting the highest at HKD 321.7. The company noted it is developing a proprietary Pan-RAS molecular glue degrader with potential differentiated advantages over existing products.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123780230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123780230","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Intraday Rise 3.94% in Regular Trading, Clinical Collaboration with Revolution Medicines on RAS Combination Therapies","media":"Market Focus","content":"<p><p>On August 11, BEONE MEDICINES rose 3.94% in regular trading, trading at 221.2 HKD/share, with turnover of HKD 157 million.</p><p>On the news front, BEONE MEDICINES announced a clinical collaboration agreement with Revolution Medicines to jointly evaluate combination therapy regimens pairing the company's clinical-stage oncology candidates with one or more of Revolution Medicines' four clinical-stage RAS(ON) inhibitors, targeting the historically \\\"undruggable\\\" RAS pathway in cancer treatment.</p><p>The collaboration follows a period of strong momentum for the company. BEONE MEDICINES reported Q2 global revenue of USD 1.705 billion, up 30% year-over-year, with GAAP net profit of USD 237 million, representing 151% growth. The company raised its full-year revenue guidance to RMB 449-462 billion. Multiple institutions including CLSA, CICC, Bank of America, and BOCOM International have recently upgraded target prices, with CLSA setting the highest at HKD 321.7. The company noted it is developing a proprietary Pan-RAS molecular glue degrader with potential differentiated advantages over existing products.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Intraday Rise 3.94% in Regular Trading, Clinical Collaboration with Revolution Medicines on RAS Combination Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Intraday Rise 3.94% in Regular Trading, Clinical Collaboration with Revolution Medicines on RAS Combination Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 11, BEONE MEDICINES rose 3.94% in regular trading, trading at 221.2 HKD/share, with turnover of HKD 157 million.</p><p>On the news front, BEONE MEDICINES announced a clinical collaboration agreement with Revolution Medicines to jointly evaluate combination therapy regimens pairing the company's clinical-stage oncology candidates with one or more of Revolution Medicines' four clinical-stage RAS(ON) inhibitors, targeting the historically \\\"undruggable\\\" RAS pathway in cancer treatment.</p><p>The collaboration follows a period of strong momentum for the company. BEONE MEDICINES reported Q2 global revenue of USD 1.705 billion, up 30% year-over-year, with GAAP net profit of USD 237 million, representing 151% growth. The company raised its full-year revenue guidance to RMB 449-462 billion. Multiple institutions including CLSA, CICC, Bank of America, and BOCOM International have recently upgraded target prices, with CLSA setting the highest at HKD 321.7. The company noted it is developing a proprietary Pan-RAS molecular glue degrader with potential differentiated advantages over existing products.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1123780230","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123780230","pubTimestamp":1786411999,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 11, BEONE MEDICINES rose 3.94% in regular trading, trading at 221.2 HKD/share, with turnover of HKD 157 million.On the news front, BEONE MEDICINES announced a clinical collaboration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"动向提醒|BEONE Medicines常规交易盘中大涨3.94%，与Revolution Medicines开展RAS联合疗法临床合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On August 11, BEONE MEDICINES rose 3.94% in regular trading, trading at 221.2 HKD/share, with turnover of HKD 157 million.On the news front, BEONE MEDICINES announced a clinical collaboration agreement with Revolution Medicines to jointly evaluate combination therapy regimens pairing the company's clinical-stage oncology candidates with one or more of Revolution Medicines' four clinical-stage RAS(ON) inhibitors, targeting the historically \\\"undruggable\\\" RAS pathway in cancer treatment.The collaboration follows a period of strong momentum for the company. BEONE MEDICINES reported Q2 global revenue of USD 1.705 billion, up 30% year-over-year, with GAAP net profit of USD 237 million, representing 151% growth. The company raised its full-year revenue guidance to RMB 449-462 billion. Multiple institutions including CLSA, CICC, Bank of America, and BOCOM International have recently upgraded target prices, with CLSA setting the highest at HKD 321.7. The company noted it is developing a proprietary Pan-RAS molecular glue degrader with potential differentiated advantages over existing products.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123780230","isCrawlerRequest":true}